Arcalyst® (rilonacept) – New orphan indication
March 18, 2021 - Kiniksa Pharmaceuticals announced the FDA approval of Arcalyst (rilonacept), for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
Download PDF
